No Data
Guangzhou LBP Medicine Science & Technology (688393.SH) and its subsidiaries have obtained multiple qualifications.
Guangzhou LBP Medicine Science & Technology (688393.SH) issued an announcement that the company and its subsidiaries will achieve domestic... in October to December 2024.
Guangzhou LBP Medicine Science & Technology (688393.SH): The HER2 gene testing kit (fluorescence in situ hybridization method) has received approval for the change of registration as medical instruments.
Gelonghui, December 31 - Guangzhou LBP Medicine Science & Technology (688393.SH) announced that the company recently received the "Medical Instruments Change Registration Document" issued by the National Medical Products Administration for the HER2 gene detection kit (fluorescence in situ hybridization method). The expected use of the product has changed from "This kit is used for the in vitro qualitative detection of the amplification of the HER2 gene in breast cancer tissue sections fixed in 10% neutral formalin and paraffin-embedded." to "This kit is used for the in vitro qualitative detection of the amplification of the HER2 gene in breast cancer and gastric adenocarcinoma tissue sections fixed in 10% neutral formalin and paraffin-embedded. For gastric adenocarcinoma,
Guangzhou LBP Medicine Science & Technology (688393.SH): The cervical cytology AI-assisted system is currently in the registration application stage for Class III certification.
On December 30, Gelonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) disclosed the record of investor relations activities indicating that the company's cervical cytology AI-assisted system is currently in the registration phase for Class III certification. The main issue this product addresses is screening work. There is a relative shortage of pathologists in the country, and cytological diagnosis particularly relies on the interpretation of doctors. The anticipated scenario is that AI will handle most of the screening work, allowing doctors to focus their main attention on suspicious points, thereby improving diagnostic efficiency and accuracy. The product has annotated over 1 million field images and over 2.6 million cells, in 9 medical centers.
Guangzhou LBP Medicine Science & Technology (688393.SH): Core technical staff Su Zhongchun has resigned.
Guangzhou LBP Medicine Science & Technology (688393.SH) announced that the company's core technical staff, Su Zhongchun, recently applied for resignation due to personal reasons...
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Earnings Quality Is Low
An Biping: Third quarter report 2024
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%
